Korea Q2 Roundup: New Drugs Drive Growth, First-Line Lazertinib Approval
New Indications For U-Turned Assets, 'Glocalization'
Aside from a mixed bag of second-quarter earnings, the latest developments in the Korean pharma industry include Hanmi’s search for new indications for u-turned assets and the approval of Yuhan’s lazertinib as a first-line treatment for NSCLC.
You may also be interested in...
Join the Pink Sheet's APAC content team for a video overview of major trends and topics in the regional biopharma industry over the past few months.
Join Scrip's APAC content team for a video overview of major trends and topics in the regional biopharma industry over the past few months.
Yuhan’s oncology drug lazertinib is set to expand its indications in Korea to the first-line treatment of EGFR mutation-positive advanced NSCLC, based on new top-line Phase III data showing clinical benefits for all patient sub-groups.